Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch

Salcedo-Villanueva, Guillermo; Feria-Anzaldo, Estephania; Romo-Aguas, Juan C.; Lisker-Cervantes, Andrés; Gonzalez-Dibildox, Alejandra; Moreno-Paramo, Edel; Medina-Andrade, A.; Vélez-Montoya, Raúl; García-Aguirre, Gerardo; Morales-Cantón, Virgilio; Quiroz‐Mercado, Hugo

doi:10.1007/s10792-018-1038-4

Cited by 7 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, it F I G U R E 5 VEGFA-mediated Vasculogenesis is regulated by miR-205-5p. 37 Similarly, anti-VEGF therapies are also helpful against different forms of cancer, such as glioblastoma and colorectal cancer. ARPE-19 control medium (A), mimic(miR-205-5p)-treated ARPE-19 control (B), H 2 O 2 600 µmol/L treated ARPE-19 (C) and mimic-treated ARPE-19 + H 2 O 2 600 µmol/L medium (D).…”

Section: Vegfa Mrna As a Mir-205-5p Targetmentioning

confidence: 99%

“…13,52 The PI3K/AKT signalling pathway induces the Nrf2/ARE antioxidant pathway, 53 Anti-VEGF administration is currently used to control neovascular processes in both DR and wet AMD. 37 Similarly, anti-VEGF therapies are also helpful against different forms of cancer, such as glioblastoma and colorectal cancer. 55 In agreement with this, miR-205-5p suppresses VEGFA expression in glioblastoma 7 and also inhibits the PI3K/AKT pathway.…”

Section: Oxidative Stress Down-regulates Mir-205-5p Expressionmentioning

confidence: 99%

“…18,32,33 In agreement with this, miR-205-5p overexpression also reduced reactive oxygen species (ROS) by increasing peroxiredoxin 2 levels, 34 suggesting that miR-205-5p could be sensitive to oxidative stimuli. 37,38 The present work focuses on the response of miR-205-5p-VEGFA in ARPE-19 cells to oxidative challenge as an approach to the potential therapeutic target of eye-related proliferative disorders. 27,29,35,36 Indeed, VEGF inhibitors are widely used in both cancer and wet AMD, with beneficial results.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Oxidative stress‐induced angiogenesis is mediated by miR‐205‐5p

Oltra

Vidal-Gil

Maisto³

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

miR‐205‐5p is known to be involved in VEGF‐related angiogenesis and seems to regulate associated cell signalling pathways, such as cell migration, proliferation and apoptosis. Therefore, several studies have focused on the potential role of miR‐205‐5p as an anti‐angiogenic factor. Vascular proliferation is observed in diabetic retinopathy and the ‘wet’ form of age‐related macular degeneration. Today, the most common treatments against these eye‐related diseases are anti‐VEGF therapies. In addition, both AMD and DR are typically associated with oxidative stress; hence, the use of antioxidant agents is accepted as a co‐adjuvant therapy for these patients. According to previous data, ARPE‐19 cells release pro‐angiogenic factors when exposed to oxidative insult, leading to angiogenesis. Matching these data, results reported here, indicate that miR‐205‐5p is modulated by oxidative stress and regulates VEGFA‐angiogenesis. Hence, miR‐205‐5p is proposed as a candidate against eye‐related proliferative diseases.

show abstract

Section: Vegfa Mrna As a Mir-205-5p Targetmentioning

confidence: 99%

Section: Oxidative Stress Down-regulates Mir-205-5p Expressionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Oxidative stress‐induced angiogenesis is mediated by miR‐205‐5p

Oltra

Vidal-Gil

Maisto³

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…There are more reports in the literature about switching from ranibizumab to aflibercept, or from bevacizumab to aflibercept or ranibizumab than the other way around [7][8][9][10][11]. The results of these studies vary: some show the effectiveness of the switch in the form of anatomical improvement (CRT) and functional improvement (BCVA) [7,9,10]; others show anatomical improvement, but no changes in BCVA [8,10,11]. The SAFARI study, in which the authors assessed the effectiveness of the switch from aflibercept to ranibizumab, showed greater anatomical than functional improvement in the studied patients [12].…”

Section: Discussionmentioning

confidence: 99%

“…It is not clear to what extent the switch from one drug to another is effective for patients. Most of the studies reported that the switch from ranibizumab to intravitreal aflibercept is effective in improving retinal architecture [5][6][7]. In Poland; however, aflibercept may be the I line drug on a par with ranibizumab as part of the Drug Program for the Treatment of Age-Related Exudative Macular Degeneration (the Program).…”

Section: Introductionmentioning

confidence: 99%

Switching Between Aflibercept and Ranibizumab in the Treatment of Refractory Exudative Age-related Macular Degeneration

2021

View full text Add to dashboard Cite

Introduction: Aflibercept and ranibizumab have become the most used drugs in the treatment of wet age-related macular degeneration. Some patients; however, do not respond to aflibercept and ranibizumab treatment. Our aim was to determine whether the switch from aflibercept to ranibizumab, and then switchback, is effective in a group of patients poorly responding to aflibercept. We assessed best corrected visual acuity, central retinal thickness, and the presence of intra- and subretinal fluid (respectively). Material and methods: We conducted a retrospective comparative case series study. Twenty eyes of 20 patients, who had no inhibition of disease activity after at least one year of treatment with aflibercept, were included in the study. If after switch to ranibizumab the response to the drug was again inadequate, we returned to aflibercept. We divided the study population into two groups: treatment- naïve and patients who had received injections before entering the Drug Program for the Treatment of Age-Related Exudative Macular Degeneration. Results: We observed an improvement in both best corrected visual acuity and central retinal thickness parameters, but only in the treatment-naïve group. We did not observe any statistically credible effects for sub- and intraretinal fluid in the studied groups. Conclusions: Drug conversion may be beneficial for patients poorly responding to primary therapy. Greater improvement is seen in previously untreated patients.

show abstract

Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study

Creuzot Garcher,

Srour,

Baudin

et al. 2023

Ophthalmol Ther

View full text Add to dashboard Cite

Introduction The aim of this study was to describe the management of neovascular age-related macular degeneration (nAMD) in French patients between 2008 and 2018. Methods This was a retrospective longitudinal cohort study using exhaustive nationwide health records from the French National Health Information database. Enrollment criteria were adults aged ≥ 50 years, nAMD diagnosis, or reimbursement for nAMD treatments (anti-vascular epithelial growth factor [VEGF] injection or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, and treatments for other macular diseases (dexamethasone implant, laser). Main outcome measures were consumption of medical care and nAMD treatments per calendar year and number of years of follow-up. Results Between 2008 and 2018, we identified 342,961 patients who have been treated for nAMD. Median duration of ophthalmological follow-up exceeded 7 years (90 months). The median annual number of ophthalmology consultations decreased from nine visits in year 1 after treatment initiation to four visits from year 7 onwards. The median duration of nAMD treatment was 10.1 months for all patients, with 48.5% of patients undergoing treatment for < 1 year. Only 24.4% of patients had maintained treatment at year 11. Patients remaining under treatment had a median of four anti-VEGF treatments per year throughout the 10-year study period. Ranibizumab was the more common first-line treatment (67.5% of patients) compared to aflibercept (32.4%). About 20% of patients who initiated treatment switched treatment at least once. Conclusions LANDSCAPE provides exhaustive nationwide data on the real-world management of nAMD in France over a 10-year period. Further investigation into short treatment duration is required, especially in terms of understanding its relation to visual outcomes. Supplementary Information The online version contains supplementary material available at 10.1007/s40123-023-00772-3.

show abstract

Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch

Cited by 7 publications

References 23 publications

Oxidative stress‐induced angiogenesis is mediated by miR‐205‐5p

Oxidative stress‐induced angiogenesis is mediated by miR‐205‐5p

Switching Between Aflibercept and Ranibizumab in the Treatment of Refractory Exudative Age-related Macular Degeneration

Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study

Contact Info

Product

Resources

About